ASSESSMENT OF VACCINATION PROGRAM EFFECTIVENESS: BASIC APPROACHES AND ISSUES

The article is dedicated to prevention of pneumococcal infections, which remain among the most common diseases in infants. The authors analyze international approaches to vaccination effectiveness assessment in light of predicting the expected effect of cohort immunization, given introduction of vaccination against this infection to the Russian National Immunization Calendar. The article presents a discussion of difficulties in interpreting epidemiological, immunological and clinical data in the absence of studies on direct
comparison of drugs. The authors demonstrate the need in multicomponent approach to immunization program effectiveness analysis, which would include optimization of epidemiological vigilance, adoption of the standard definition of a case, registration of results of prelicensure clinical trials of vaccines and postlicensure follow-up in similar groups of patients.

1. Briko N.I. Evaluation of the quality and effectiveness of the immunization. Lechashchii vrach – The attending physician. 2012; 10−12. Available at: http://www.lvrach.ru/2012/10/15435557

2. English-Russian Glossary of Key Terms on Vaccinology and Immunization. 2009

3. Note for Guidance on the Clinical Evaluation of Vaccines. 2005.

4. Plotkin S.A. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J. 2001; 20: 63–75.

5. Plotkin S.A. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008; 47: 401–9.

6. Plotkin S.A. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010; 17: 1055–65.

7. Siegrist C.-A. Vaccine immunology. In: Plotkin S.A., Orenstein W.A., Offit P.A., eds. Vaccines. 6th ed. Philadelphia, PA: Saunders Elsevier. 2012.

8. Moser M., Leo O. Key concepts in immunology. Vaccine. 2010; 28 (Suppl. 3): C2–13.

9. Pulendran B., Ahmed R. Immunological mechanisms of vaccination. Nat Immunol. 2011; 12: 509–17.

10. Male D., Brostoff J., Roth D. et al. Immunology. 7th ed. Philadelphia, PA: Mosby Elsevier. 2006.

11. Abbas A.K., Lichtman A.H., Pillai S. et al Cellular and Molecular Immunology. 6th ed. Philadelphia, PA: Saunders Elsevier. 2007.

12. Dieffenbach C.W., Tramont E.C., Plaeger S.F. Innate (general or nonspecific) host defense mechanisms. In: Mandell G.L., Bennett J.E., Dolin R., eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, PA: Churchill Livingstone Elsevier. 2010. Р. 37−48.

13. Buckley R.H. The T-, B-, and NK-cell systems. In: Behrman R.E., Kliegman R.M., Jenson H.B., eds. Nelson Textbook of Pediatrics. 17th ed. Philadelphia, PA: Saunders Elsevier. 2004. Р. 683−689.

14. Chen C.Y., Hsu H.Y., Liu C.C., Chang M.H., Ni Y.H. Stable seroepidemiology of hepatitis B after universal immunization in Taiwan: a 3-year study of national surveillance of primary school students. Vaccine. 2010; Iss. 28: 5605−5608.

15. Martin C.J. et al. Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity. J Infect Dis. 2008; Iss. 197 (5).

16. Andrews N.J., Waight P.A., Birbidge P. et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Available at: www.thelancet.com/infection. Published online July 18, 2014. Available at: http://dx.doi.org/10.1016/S1473-3099(14)70822-9

17. Lee L.H., Frasch C.E., Falk L.A., Klein D.L., Deal C.D. Correlates of immunity for pneumococcal conjugate vaccines. Vaccine. 2003; 21: 2190–6.

18. Siber G.R., Chang I., Baker S. et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies 29. Vaccine. 2007; 25: 3816–26.

19. Cutts F.T., Zaman S.M., Enwere G. et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in the Gambia: randomised, double-blind, placebo-controlled trial. Lancet. 2005; 365: 1139–46.

20. Saaka M., Okoko B.J., Kohberger R.C. et al. Immunogenicity and serotype-specific efficacy of a 9-valent pneumococcal conjugate vaccine (PCV-9) determined during an efficacy trial in the Gambia. Vaccine. 2008; 26: 3719–26.

21. Jokinen J.T., Ahman H., Kilpi T.M., Makela P.H., Kayhty M.H. Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media. J Infect Dis. 2004; 190: 545–50.

22. Instruktsiya po primeneniyu Pnevmo 23 (vaktsina pnevmokokkovaya polivalentnaya polisakharidnaya) ot 24.08.2005 № 01-11/165-05 [Instructions for Application Pneumo 23 (Pneumococcal Vaccine Polyvalent Polysaccharide) dated 24.08.2005 № 01-11 / 165-05].

23. Instruktsiya po primeneniyu lekarstvennogo preparata dlya meditsinskogo primeneniya Prevenar 13 ot 12.07.2012. LP 000798-120712 [Patient Information Leaflet for Prevenar 13 dated 12.07.2012. LP 000798-120712].

24. Instruktsiya po primeneniyu lekarstvennogo preparata dlya meditsinskogo primeneniya Sinfloriks LP 001412-110112 [Patient Information Leaflet for Sinfloriks LP 001412-110112].

25. EMEA. Summary of product characteristics Synflorix. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000973/human_med_001071.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124

26. Murray P.R., Rosenthal K.S., Pfaller M.A. Medical Microbiology. 6th ed. Philadelphia, PA: Mosby Elsevier. 2009.

27. Fitzwater S.P., Chandran A., Santosham M., Johnson H.L. The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2012; 31: 501–8.

28. Isaacman D.J., McIntosh E.D., Reinert R.R. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis. 2010; 14: e197–209.

29. Dagan R. New insights on pneumococcal disease: What we have learned over the past decade. Vaccine. 2009; 27S: C3–5.

30. Pneumococcal vaccines WHO position paper 2012. Weekly epidemiological record. 2012; 87 (14): 129–144.

31. Muñoz-Almagro C. et al. Epidemiologic and Clinical Implications of Second-Generation Pneumococcal Conjugate Vaccines. Current Infectious Disease Reports. 2013; 15 (2): 184–190.

32. Van Hoek A.J. et al. Effect of Serotype on Focus and Mortality of Invasive Pneumococcal Disease: Coverage of Different Vaccines and Insight into Non-Vaccine Serotypes. PLoS ONE. URL: (www.plosone.org). July 2012; 7 (Issue 7).

33. Hausdorff W.P., Feikin D.R., Klugman K.P. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis. 2005; 5: 83–93.

34. Weinberger D.M. et al. Association of Serotype with Risk of Death Due to Pneumococcal Pneumonia: A Meta-Analysis. Clinical Infectious Diseases. 2010; 51 (6): 692–699.

35. Richter S.S. et al. Pneumococcal Serotypes before and after Introduction of Conjugate Vaccines, United States, 1999–2011. Emerging Infectious Diseases. Available at: www.cdc.gov/eid. July 2013; 19 (7).

36. European Centre for Disease Prevention and Control. Surveillance of invasive pneumococcal disease in Europe, 2010. Stockholm: ECDC. 2012. Doi 10.2900/65655.

37. UK Health Service HPA. Available at: http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Pneumococcal/EpidemiologicalDataPneumococcal/CurrentEpidemiologyPneumococcal/InPrevenar13NotInPrevenarPCV7

38. Steens A., Riise Bergsaker M.A. et al. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine. 2013. Available at: http://dx.doi.org/10.1016/j.vaccine.2013.10.032

39. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Available at: www.thelancet.com/respiratory Published online April 10, 2014. Available at: http://dx.doi.org/10.1016/S2213-2600(14)70060-8

40. Hortal M. et al. Hospitalized children with pneumonia in Uruguay: Pre and post introduction of 7 and 13-valent pneumococcal conjugated vaccines into the National Immunization Program. Vaccine. 2012; 30 (33): 4934–4938.

41. Palmu A.A., Jokinen J. et al. Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3–4 trial. Available at: www.thelancet.com/infection Published online November 26, 2013. Available at: http://dx.doi.org/10.1016/S1473-3099(13)70338-4

42. Van den Bergh M.R., Spijkerman J., Swinnen K.M., Francois N.A., Pascal T.G., Borys D. et al. Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial. Clin Infect Dis. 2013; 56 (3): 30–39.

43. Rinta-Kokko et al. ISPPD 2014. Abstract 0560.

44. The resolution of the meeting of the Public Coordination Council for pneumococcal disease in Russia. Voprosy sovremennoi pediatrii – Current pediatrics. 2012; 11 (4): 68–69.

45. PHARMAC. Available at: http://www.pharmac.health.nz/news/item/national-immunisation-schedule

46. Qauch C. Vaccination against pneumococcal disease in Canada. Pediatricheskaya farmakologiya – Pediatric pharmacology. 2014; 11 (1): 16–19.

47. Nuorti P. et al. OP-239. ISPPD 2014.

48. Data from Finland The National Institute for Health and Welfare (THL) Last update: 06.06.2013; 22: 24. Available at: http://www3.thl.fi/stat/

49. Kovtun O.P., Romanenko V.V. Effectiveness of pneumococcal conjugate vaccines next generation in different regions of the world. Voprosy sovremennoi pediatrii – Current pediatrics. 2014; 13 (1): 18–25.

50. The resolution of the meeting of the Coordinating Council for Public pneumococcal disease and vaccination in Russia. Pediatricheskaya farmakologiya – Pediatric pharmacology. 2013; 10 (6): 98–100.

51. Katosova L.K. Kliniko-biologicheskaya otsenka pnevmotropnoi flory pri ostrykh i khronicheskikh bronkholegochnykh boleznyakh u detei. Avtoref. …dis. dokt. biol. nauk [Clinical and Biological Assessment of Pneumotropic Flora in Acute and Chronic Bronchopulmonary Diseases in Cchildren. Author’s abstract]. Moscow,1990. 43 p.

52. Kozlov R.S., Krechikova O.I., Sivaya O.V. Antimicrobial resistance in Streptococcus pneumonia Russia: results of a prospective multicenter study (Phase A Project Pegasus-I). Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya – Clinical microbiology and antimicrobial chemotherapy. 2002; 4 (3): 267–277.

53. Kozlov R.S. Pnevmokokki: proshloe, nastoyashchee i budushchee [Pneumococci: Past, Present and Future]. Smolensk, 2005.

54. Beloshitskii G.V., Koroleva I.S. Drug resistance pneumococci isolated from cerebrospinal fluid and blood of patients with meningitis. Epidemiologiya i infektsionnye bolezni – Epidemiology and infectious diseases. 2006; 3: 32–36.

55. Martynova A.V., Turkutyukov V.B. Epidemiological analysis of the incidence of invasive and non-invasive forms of pneumococcal disease in different populations. Vestnik Rossiiskoi AMN – Annals of the Russian Academy of Medical Sciences. 2007; 9: 12–16.

56. Beloshitskii G.V., Koroleva I.S., Koshkina N.A. Pneumococcal meningitis in the Russian Federation. Epidemiologiya i vaktsinoprofilaktika – Epidemiology and vaccination. 2009; 2 (45): 21–26.

57. Koroleva I.S., Kharit S.M., Ruleva A.A. et al. Pneumococcal infection in Russia - the epidemiological situation. Pediatricheskaya farmakologiya – Pediatric pharmacology. 2010; 7 (4).

58. Mayanskii N.A., Alyab'eva N.M., Katosova L.K. et al. Definition of capsular serotypes by multiplex PCR. Voprosy diagnostiki v pediatrii – Diagnostics in pediatrics. 2010; 2 (6): 6–10.

59. Mironov K.O., Platonov A.E., Kozlov R.S. Identification and serotyping of Streptococcus pneumoniae strains Russian using techniques based on PCR. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya – Clinical microbiology and antimicrobial chemotherapy. 2011; 13 (4): 304–313.

60. Sidorenko S.V., Savinova T.A., Il'ina E.I. et al. Population structure of pneumococci with reduced susceptibility to penicillin and perspectives of antipneumococcal vaccination to reduce the spread of antibiotic resistance. Antibiotiki i khimioterapiya – Antibiotics and chemotherapy. 2011; 5 (6): 2–10.

61. Koroleva I.S., Beloshitskii G.V. Epidemiological characteristics of pneumococcal meningitis in children under the age of 6 years in the Russian Federation. Epidemiologiya i infektsionnye bolezni. Aktual'nye voprosy – Epidemiology and infectious diseases. Topical issues. 2012; 1: 18–21.

62. Alyabyeva N.M., Mayanskiy N.A. et al. Serotype distribution and antibiotic resistance of Streptococcus pneumoniae isolated from children with acute otitis media in Russia, in ESPID 2012. Thessaloniki, Greece. 2012.

63. Mayanskiy N.A., Alyabyeva N.M., Lazareva A.V., Ponomarenko O., Katosova L.G., Ivanenko A.I., Kulichenko T.V., Namazova-Baranova L.S. Nasopharyngeal carriage of Streptococcus pneumoniae in children with acute bacterial infection in Russia, in ESPID 2012. Thessaloniki, Greece. 2012.

64. Somatova E.V., Drui A.U., Tsaur G.A., Boronina L.G. Serotyping strains of Streptococcus pneumoniae, isolated from children in the Middle Urals, by multiplex PCR. Epidemiologiya i infektsionnye bolezni – Epidemiology and infectious diseases. 2012; 5: 25–30.

65. Lobzin Yu.V., Sidorenko S.V., Kharit S.M. et al. Serotypes of Streptococcus pneumoniae, the leading cause nosological forms of pneumococcal infections. Zhurnal infektologii – Journal of infectology. 2013; 5 (4): 35–41.

66. Baranov A.A., Namazova-Baranova L.S., Mayanskii N.A., Kulichenko T.V., Polunina T.A., Lazareva A.V. et al. The role of Streptococcus pneumoniae in the structure of bacterial infections in children admitted to hospitals in Moscow in 2011-2012. Pediatricheskaya farmakologiya – Pediatric pharmacology. 2013; 10 (5): 1–10.

67. Kozlov R.S., Krekshina O.I., Murav'ev A.A., Mironov K.O., Platonov A.E., Dunaeva E.A., Tatochenko V.K. et al. The results of prevalence studies in Russian community-acquired pneumonia and acute otitis media in children aged up to 5 years (PAPIRUS). The role of S. pneumoniae and H. influenzae in the etiology of these diseases. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya – Clinical microbiology and antimicrobial chemotherapy. 2013; 15 (4): 246–257.

68. Fel'dblyum I.V., Semerikov V.V., Golodnova S.O. et al. The results of serotyping strains of S. pneumoniae, circulating in the city of Perm. Zdorov'e sem'i ― 21-i vek. Elektronnoe periodicheskoe izdanie – Family Health - 21st century. Electronic periodical. 2013; 2. Available at: http://www.fh-21.perm.ru/download/2013-2-15.pdf

69. Beloshitskii G.V., Koroleva I.S. Serotype characteristic of S. pneumoniae strains in Moscow. Epidemiologiya i vaktsinoprofilaktika – Epidemiology and vaccination. 2014; 1 (74): 90–96.

70. Mayanskiy N., Alyabieva N., Ponomarenko O., Lazareva A., Katosova L., Ivanenko A., Kulichenko T., Namazova-Baranova L., Baranov A. Serotypes and antibiotic resistance of non-invasive Streptococcus pneumoniae circulating in pediatric hospitals in Moscow, Russia. Int J Infect Dis. 2014; 20: 58–62.

71. Tatochenko V. et al. Streptococcus pneumoniae serotype distribution in children in the Russian Federation before the introduction of pneumococcal conjugate vaccines into the National Immunization Program. ERV. 2014; 13 (2): 257–264.

72. Il'ina S.V., Beletskaya O.A., Sabitov A.U. The results of evaluation of the effectiveness and safety of conjugate pneumococcal vaccines in the Russian Federation. Epidemiologiya i infektsionnye bolezni – Epidemiology and infectious diseases. 2013; 6: 55–59.

73. Sabitov A.U., Kharitonov A.N., Budalina S.V., Rozhkova L.V. Vaccination for pneumococcal infections of children at-risk groups to be vaccinated universal. Zhurnal infektologii – Journal of infectology. 2012; 4 (4): 35–36.

74. Rudakova A.V., Uskov A.N., Kharit S.M., Sidorenko S.V. Pharmacoeconomic aspects of pneumococcal vaccination of children in Russia. Zhurnal infektologii – Journal of infectology. 2011; 3 (4): 78–83.

75. Rudakova A.V., Baranov A.A., Lobzin Yu.V. et al. Pharmacoeconomic aspects of vaccination of children 13-valent pneumococcal conjugate vaccine in the Russian Federation. Voprosy sovremennoi pediatrii – Current pediatrics. 2014; 1: 34–411.